en
Scientific article
Open access
English

Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective

Published inClinical Microbiology and Infection, vol. 23, no. 9, p. 659-666
Publication date2017
Abstract

Few industry-independent studies have been conducted to compare the relative costs and benefits of drugs to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies-linezolid versus trimethoprim-sulfamethoxazole plus rifampicin-for the treatment of MRSA infection.

Citation (ISO format)
VON DACH, Elodie et al. Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of methicillin-resistant Staphylococcus aureus infection: a healthcare system perspective. In: Clinical Microbiology and Infection, 2017, vol. 23, n° 9, p. 659–666. doi: 10.1016/j.cmi.2017.02.011
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1198-743X
443views
236downloads

Technical informations

Creation10/20/2017 7:25:00 PM
First validation10/20/2017 7:25:00 PM
Update time03/15/2023 2:20:53 AM
Status update03/15/2023 2:20:52 AM
Last indexation09/25/2023 7:53:00 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack